Rectal non-Hodgkin's lymphoma in an infliximab treated patient with ulcerative colitis and primary sclerosing cholangitis.
A 20-year old man with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC) was diagnosed with a rectal non-Hodgkin's lymphoma (NHL) at surveillance endoscopy while being in remission on infliximab therapy. Further staging identified a diffuse large B-cell NHL, EBV negative restricted to the rectal submucosa (stage IA). Until now, there has not been any evidence of an increased risk of NHL in patients with UC nor of an increased risk of lymphoproliferative disorders in IBD patients. Hence, the role of concomitant PSC in the pathogenesis of intestinal NHL is unclear. However, IBD patients treated with purine analogues and with anti-TNF are at risk of NHL, especially hepatosplenic T-cell lymphoma. The management of this particular young patient is further complicated by the possibility of a future colectomy due to intractable disease which compromises the use of radiotherapy for this localized disease.
Division of Gastroenterology and Hematology, University Hospitals Leuven, Belgium.
Valérie
V
Van Hauwaert
Stef
S
Meers
Gregor
G
Verhoef
Thomas
T
Tousseyn
Xavier
X
Sagaert
Séverine
S
Vermeire
Paul
P
Rutgeerts
Gert
G
Van Assche
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001706:Biopsy; D015209:Cholangitis, Sclerosing / Q000150:complications* / Q000188:drug therapy; D003093:Colitis, Ulcerative / Q000150:complications* / Q000188:drug therapy; D003113:Colonoscopy; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006801:Humans; D000069285:Infliximab; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications* / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D012004:Rectal Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000473:pathology*; D055815:Young Adult
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab